Well-Funded Seres Races To Be First To Market With A Microbiome Drug
This article was originally published in The Pink Sheet Daily
Executive Summary
After raising $143 million from an IPO in June, Seres Therapeutics is hoping its lead development candidate SER-109, in Phase II for Clostridium difficile, could be the first microbiome-based drug to reach the market.
You may also be interested in...
Seres Argues Different Diagnostic Needed In Recurrent C. Difficile Trials
As it talks study design with FDA, Seres says new analysis of Phase II trial of microbiome candidate SER-109 suggests that a C. difficile cytotoxin test would be more accurate and that a higher dose may be more effective.
Q4 Earnings Preview: Setting The Tone For 2022 (Part 1)
Biopharma will outline its growth goals for 2022 over the coming weeks, with J&J, Novartis, AbbVie, Merck, Roche, Biogen and Lilly among the first to report.
Lots To Celebrate Among 2021 Drug Launches, But Underlying Trends Underwhelm
The number of new drugs that launched in 2021 was on par with recent high trends, but launch trajectories generally underwhelmed commercially – except for COVID-19 vaccines.